Fibrosis

Atrophy (14)
Bleeding (66)
Disability (104)
Fever (40)
Fibrosis (56)
Headache (11)
Malignancy (12)
Preeclampsia (11)
Sclerosis (17)
Sickness (10)
Ulcer (28)

Synopsis: Domenii: Health: Health generale: Illness: Signs and symptoms: Fibrosis:

had less cardiac fibrosis, were experienced more active less age-related slowing of their metabolic rate, produced less cholesterol,

It will allow for rapid population-scale DNA sequencing across a broad range of disease areas, focusing on diseases with significant unmet clinical need such as amyotrophic lateral sclerosis (ALS) and idiopathic pulmonary fibrosis.

especially with widespread skin involvement and internal organ fibrosis, will see their lives cut short. Scleroderma many pathways he majority of drug treatments that exist today for fibrosis basically look at reducing just the inflammation,

says Dinesh Khanna, associate professor of internal medicine at the University of Michigan. here are other drugs that block one or two of the signaling pathways that cause the disease,

Neubig says. ur research shows promise for the development of a new drug that can reverse the fibrosis process by flipping the main switch on all of the signaling pathways.

and kidney fibrosis Bhatia says. The research was funded by the Koch Institute Frontier Research Fund the Kathy and Curt Marble Cancer Research Fund the Mazumdar-Shaw International Oncology Fellows Program the Burroughs Wellcome

#Researchers Identify a New Culprit Behind Fibrosis An international team of researchers has identified a new molecule involved in skin fibrosis,

The new study is the first to investigate the role of this molecule in skin fibrosis

The study reveals a new mechanism for the development of fibrosis in skin tissues and could potentially be relevant to other organs that develop fibrosis such as the lungs, heart,

liver and kidney, said researchers. The team led by bioengineering professor Shyni Varghese at the University of California, San diego and Colin Jamora,

a biologist at the IFOM-instem Joint Research Laboratory in India, published the findings in the Oct 15 issue of Nature Communications. ee identified a new component that hasn previously been studied as a factor contributing to fibrosis,

said Varghese. his discovery gives us a new understanding of how fibrosis forms and could help us develop therapeutic strategies that are more effective than existing ones. ibrosis is a condition in which tough,

Due to the development of tough, fibrous matter, fibrosis causes the affected tissues to stiffen, swell, and eventually lose their normal functions.

The exact mechanism by which fibrosis develops is understood not yet clearly, and there are no proven cures or treatments for the disease.

In this study, researchers discovered that a molecule called fibulin-5 played a role in the development of skin fibrosis in mice.

and little is known about its contribution to fibrosis. Since a large component of connective tissue is made of collagen,

most research on the underlying cause of fibrosis has focused so far on the overproduction of collagen.

By focusing on elastin, the team discovered that the development of fibrosis in skin tissues was linked to a particular molecule:

fibulin-5. Researchers studied mice that were engineered genetically to develop skin fibrosis and found substantially higher levels of fibulin-5 in their skin tissues than in normal mice.

High levels of fibulin-5 were also found in the skin tissues of human patients with skin fibrosis.

Researchers also demonstrated that removing fibulin-5 from the genetically engineered mice before they developed skin fibrosis helped prevent all the symptoms of skin fibrosis including skin tissue inflammation

and stiffening from occurring. anipulating the fibulin-5 levels could be a therapeutic strategy to treat skin fibrosis,

and determine whether fibulin-5 plays a role in fibrosis development in other organs besides the skin.

'When there is scar tissue in the heart or fibrosis, this can cause part of the wave to slow down.

'When there is scar tissue in the heart or fibrosis, this can cause part of the wave to slow down.

Next, focusing on nonalcoholic steatohepatitis (NASH), the researchers found eightfold increases in potency when animals were treated with SNAS and a 30 percent greater reduction in the animals'fibrosis score.

"Patricia Moore, 63, from Oswestry was diagnosed with idiopathic pulmonary fibrosis in 2011 and received a transplant in 2014.

'When there is scar tissue in the heart or fibrosis, this can cause part of the wave to slow down.

hen there is scar tissue in the heart or fibrosis, this can cause part of the wave to slow down.

hen there is scar tissue in the heart or fibrosis, this can cause part of the wave to slow down.

#New approach for treating idiopathic pulmonary fibrosis Arrayprof. Dr. Oliver Eickelberg and Dr. Claudia Staab-Weijnitz of the Comprehensive Pneumology Center (CPC) at Helmholtz Zentrum München and their colleagues at LMU University Hospital in Munich and Yale university

which involve initial inflammation, fibrosis, and then resolution thereof, occur in the lung. Using novel mass spectrometry techniques,

The findings of the research team will provide an important basis for further translational research on the development of pulmonary fibrosis*and chronic lung diseases in general,

and abundance of proteins in patients with lung fibrosis and healthy individuals and will therefore likely lead to new approaches for the treatment of chronic lung diseases in general and lung fibrosis in particular,

#Researchers show that telomeres are linked to the origins of idiopathic pulmonary fibrosis Samples from mouse lungs show collagen fibers that generate pulmonary fibrosis.

These results suggest that idiopathic pulmonary fibrosis may be treated by therapies based on the activation of the enzyme telomerase.

Idiopathic pulmonary fibrosis (IPF) causes a gradual loss of respiratory capacity and can be lethal within a few years.

are at the origin of pulmonary fibrosis. This is the first time that telomere damage has been identified as a cause of the disease.

Idiopathic pulmonary fibrosis is a respiratory disease? affecting about 8, 000 people in Spain? in which scars are formed in lung tissue that make it rigid, leading to breathing difficulties.

For example, the telomeres of many patients suffering from idiopathic pulmonary fibrosis are shorter than normal.

Furthermore, pulmonary fibrosis is one of the most frequent illnesses among people with mutations in genes involved in telomere maintenance.

most of the animals developed progressive pulmonary fibrosis. The researchers, after finding that the lack of telomeres is lethal for type II alveolar cells,

that telomere damage may cause pulmonary fibrosis. In the words of Martínez: e have seen that acute telomere damage is sufficient to trigger pulmonary fibrosis, even in the absence of environmental damage.

A MODEL THAT REPRODUCES THE DISEASE IN HUMANS Although the mouse lacking telomeres in pulmonary epithelial cells proves the importance of telomeres in the origin of fibrosis,

it does not however reproduce the disease in most human patients. In humans, environmental hazards play an important role in the disease.

which leads to fibrosis. The researchers therefore developed an animal model that combines premature shortening of the telomeres due to telomerase deficiency, with low doses of environmental damage.

but not enough to cause pulmonary fibrosis in normal mice at the low doses administered by the authors.

The shortening of the telomeres is not in itself sufficient to generate fibrosis nor, in general, is bleomycin at low doses;

and this triggers pulmonary fibrosis, says Povedano. The new animal models are essential for testing new herapeutic strategies based on the activation of telomerase the enzyme that repairs telomeres,

fits in well with the fact that idiopathic pulmonary fibrosis only occurs in people over 50 years of age;

such as the shortening of telomeres, has enabled us to generate animal models that faithfully reproduce diseases such as idiopathic pulmonary fibrosis,

On histological examination 8 weeks after transplantation, left ventricular (LV) remodeling was attenuated significantly compared with the sham group (cardiomyocyte size and interstitial fibrosis were measured.

< Back - Next >

Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011